What The Financials Tell Us About AcelRx Pharmaceuticals Inc. (ACRX)

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) trading with an addition of $0.01 to $1.01 on Friday, an upside of 1.18 percent. An average of 655,527 shares of common stock have been traded in the last five days. There was a gain of $0.0076 in the past week. The last 20 days have seen an average of 665,642 shares traded, while the 50-day average volume stands at 1,023,763.

ACRX stock has decreased by -3.85% in the last month. The company shares reached their 1-month lowest point of $0.9100 on 10/08/21. With the stock rallying to its 52-week high on 02/09/21, shares of the company touched a low of $0.75 and a high of $2.94 in 52 weeks. In spite of this, the price is down -65.59% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

AcelRx Pharmaceuticals Inc. (ACRX) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 31.98 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 0.88. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 38.84.

The quick ratio of AcelRx Pharmaceuticals Inc. for the three months ended June 29 was 3.80, and the current ratio was 3.90, indicating that the company is able to meet its debt obligations. On the profitability front, the trailing 12-month gross margin is -70.90% against a 5-year average of -59.6%. AcelRx Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -712.89%. Its gross profit as reported stood at -$0.62 million compared to revenue of $5.42 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, AcelRx Pharmaceuticals Inc.’s return on assets was -49.00%, compared to -49.2% over the last five years.

Earnings Surprise

For the three-month period that ended June 29, AcelRx Pharmaceuticals Inc. had $29.0 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $0.44 million in the quarter, while revenues of $0.51 million were shrunk -563.64%. The analyst consensus anticipated AcelRx Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.08 per share, but it turned out to be -$0.08, a 0.00% surprise. For the quarter, EBITDA amounted to -$9.44 million. Shareholders own equity worth $119.18 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at AcelRx Pharmaceuticals Inc. (ACRX) price momentum. RSI 9-day as of the close on 07 October was 46.71%, suggesting the stock is Neutral, with historical volatility in this time frame at 23.23%.

As of today, ACRX’s price is $1.0115 +0.75% or $0.0076 from its 5-day moving average. ACRX is currently trading -0.24% lower than its 20-day SMA and -21.12% lower than its 100-day SMA. However, the stock’s current price level is -15.20% below the SMA50 and -17.27% below the SMA200.

The stochastic %K and %D were 44.31% and 40.17%, respectively, and the average true range (ATR) was 0.0473. With the 14-day stochastic at 63.29% and the average true range at 0.0493, the RSI (14) stands at 44.97%. The stock has reached -0.0050 on the 9-day MACD Oscillator while the 14-day reading was at -0.0123.

Analyst Ratings

Credit Suisse downgraded AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for AcelRx Pharmaceuticals Inc. (ACRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ACRX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.

What is ACRX’s price target for the next 12 months?

Analysts predict a range of price targets between $5.00 and $9.00, with a median target of $7.00. Taking a look at these predictions, the average price target given by analysts for AcelRx Pharmaceuticals Inc. (ACRX) stock is $7.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam